GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?
How do we assess the overall benefit and value of GLP1-RAs? Current clinical trials often focus narrowly on individual atherosclerotic cardiovascular endpoints like MACE, potentially missing broader GLP-1 RA benefits across multiple comorbidities. Herein, we set out a framework for expanding outcome...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
Elsevier,
2024-06-01T00:00:00Z.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Accesso online
Connect to this object online.3rd Floor Main Library
| Collocazione: |
A1234.567 |
|---|---|
| Copia 1 | Disponibile |